Working together for
a remedy against glaucoma
PX-medical is targeting the minimally invasive glaucoma surgical (MIGS) market that is to be poised for explosive growth to reach $900 million by 2021. Glaucoma is a complex disease in which damage to the optic nerve leads to progressive, irreversible vision loss. Glaucoma is one of the leading causes of irreversible blindness worldwide with primary open-angle glaucoma as the most common type. Although a lot of research has been done on this debilitating disease, the mechanism(s) underlying optic nerve injury in glaucoma remain poorly understood, and good diagnosis and treatment options are lacking.
PX-medical is now embarking on the intriguing finding of several studies that intracranial pressure is significantly lower in many patients suffering from glaucoma, indicating that glaucoma is a condition that develops from a mismatch in pressures across the lamina cribrosa, and that impaired cerebrospinal fluid dynamics are involved in the pathophysiology of glaucomatous optic neuropathy. The company is developing its proprietary InCalltm Technology to meet the need of Glaucoma patients, and will also develop its products in retinal diseases, Alzheimer’s Disease and neurodegenerative diseases.